Chemoradiation is considered a reasonable treatment option for patients with locally advanced, unresectable pancreatic cancer. The chemotherapy agents 5-fluorouracil, gemcitabine, capecitabine and ...

Classification of Locally Advanced Pancreatic Adenocarcinoma Into Type A and B and Comparison With Definitions Used ... we would complete neoadjuvant therapy with chemoradiation delivered with ...

Pancreatic ductal adenocarcinoma (PDAC ... Cullen and colleagues conducted a prior trial for patients with unresectable pancreatic cancer, and three of the 14 patients survived beyond 9 years.

Novocure (NVCR) plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3. The company is also exploring the use of TTFields ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

evaluated TTFields therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The trial met its primary ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other ...